Overcoming resistance to conventional drugs in Ewing’s sarcoma and identification of molecular predictors of outcome.
The improvement of Ewing's sarcoma (EWS) therapy is currently linked to find strategies to select patients with poor and good prognosis at diagnosis and to generate modified treatment regimens. In this study, we analyze the molecular factors governing EWS response to chemotherapy in order to identify genetic signatures that may be used for risk-adapted therapy.
Provenance — who produced it, who reused it
Linked to 11 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- YB-1 regulates stress granule formation and tumor progression by... 2015 · 287 cites
- Long noncoding RNA EWSAT1-mediated gene repression facilitates E... 2014 · 101 cites
- Systematic multi-omics cell line profiling uncovers principles o... 2022 · 81 cites
- Cooperation of cancer drivers with regulatory germline variants... 2019 · 72 cites
7 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently